Related Experiment Videos

A sequential histological study of bone marrow fibrosis in idiopathic myelofibrosis

H Hasselbalch1, I Lisse

  • 1Department of Medicine, Gentofte University Hospital, Denmark.

Insights

Idiopathic myelofibrosis bone marrow fibrosis can regress with specific treatments like immunosuppressants, splenectomy, or chemotherapy. However, in most chronic cases, fibrosis remains stable.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Idiopathic myelofibrosis (IMF) is characterized by bone marrow fibrosis.
  • Understanding fibrosis progression and treatment impact is crucial for patient management.

Purpose of the Study:

  • To investigate connective tissue accumulation in bone marrow during idiopathic myelofibrosis.
  • To evaluate the influence of therapy on bone marrow fibrosis in IMF patients.

Main Methods:

  • Sequential histological analysis of bone marrow biopsies from 36 patients.
  • Semiquantitative grading of bone marrow fibrosis (0-5 scale).
  • Tracking fibrosis changes over median follow-up periods of 25 months (chronic) and 2 months (acute).

Main Results:

  • Bone marrow fibrosis remained largely unchanged in most chronic IMF patients.
  • Fibrosis regression observed in 9 chronic IMF patients treated with immunosuppressants/cytotoxics or splenectomy.
  • Complete resolution of severe fibrosis occurred in one acute IMF patient with intensive chemotherapy.
  • No correlation found between spleen size and bone marrow fibrosis degree.

Conclusions:

  • Therapeutic interventions, including immunosuppressive/cytotoxic agents, splenectomy, and chemotherapy, can induce regression of bone marrow fibrosis in idiopathic myelofibrosis.
  • Bone marrow fibrosis in chronic IMF is often stable, but treatment offers potential for reversal.
  • Spleen size is not a reliable indicator of fibrosis severity in IMF.

Related Concept Videos